STOCK TITAN

Kyverna Therapeutics (KYTX) Financials

KYTX NASDAQ
FY2025 annual
Net Income -$161.3M n/m YoY
EPS (Diluted) -$3.64 n/m YoY
Free Cash Flow -$153.7M n/m YoY
Operating Cash Flow -$153.7M n/m YoY
Market Cap $276.3M as of Nov 19, 2026
Price / Sales n/m no revenue reported
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 2.1x on $133.2M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 19, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the KYTX SEC filings page.

This page shows Kyverna Therapeutics, Inc. (KYTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI KYTX FY2025

Kyverna's reported economics are dominated by development spending, with operating cash use funded largely through external financing.

The near match between the 2025 net loss of $161.3M and operating cash flow of -$153.7M indicates that reported losses are translating into cash use rather than being mostly non-cash. Free cash flow was -$153.7M while capital expenditures were only $5K, so the cash requirement comes primarily from ongoing operations and development activity.

Research and development reached $133.7M versus selling, general and administrative expense of $36.1M, making development the central use of the cost base. Both expanded in FY2025, with supplied increases of 18.9% and 19.8%, respectively, showing that spending remained elevated even as the net loss widened.

A current ratio of 7.8x and debt-to-equity of 0.1x describe a balance sheet with substantial short-term coverage and limited debt relative to equity. Financing cash flow moved from $337.1M in FY2024 to $141.2M in FY2025, indicating that external funding has been an important counterweight to operating cash use.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Kyverna Therapeutics, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
1/6

Kyverna Therapeutics, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing
N/A

Kyverna Therapeutics, Inc. reported a net loss of $161.3M while operations used $153.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Kyverna Therapeutics, Inc. reported an operating loss of $169.8M against $489K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA
-$42.6M
YoYn/m
QoQn/m

Kyverna Therapeutics, Inc.'s EBITDA was -$42.6M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$41.9M
YoYn/m
QoQn/m

Kyverna Therapeutics, Inc. reported a net loss of $41.9M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.68
YoYn/m
QoQn/m

Kyverna Therapeutics, Inc. earned -$0.68 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q3 2026.

Cash & Balance Sheet

Free Cash Flow
-$35.5M
YoYn/m

Kyverna Therapeutics, Inc. recorded an outflow of $35.5M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Cash & Debt
$31.8M
YoY-6.9%
QoQ0.0%

Kyverna Therapeutics, Inc. held $31.8M in cash against $25.0M in long-term debt as of Q3 2026.

Shares Outstanding
63M
YoY+44.4%
QoQ+2.2%

Kyverna Therapeutics, Inc. had 63M shares outstanding in Q3 2026. This represents an increase of 44.4% from the same quarter a year earlier. Against the prior quarter it is up 2.2%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-31.5%
YoY-7.3pp
QoQ-8.3pp

Kyverna Therapeutics, Inc.'s quarterly ROE was -31.5% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 7.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 8.3 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$27.0M
YoY-11.3%
QoQ+9.0%

Kyverna Therapeutics, Inc. invested $27.0M in research and development in Q3 2026. This represents a decrease of 11.3% from the same quarter a year earlier. Against the prior quarter it is up 9.0%.

Capital Expenditures
$174K
YoY+8600.0%

Kyverna Therapeutics, Inc. invested $174K in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 8600.0% from the same quarter a year earlier.

Share Buybacks

Not reported for Q3 2026.

KYTX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KYTX quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
R&D Expenses$27.0M-11.3%$24.8M-30.8%$30.1M-19.7%$30.0M-10.4%$30.5M+4.3%$35.8M+31.1%$37.4M+66.5%$33.5M+95.1%
SG&A Expenses$15.9M+92.0%$14.8M+71.8%$11.3M+13.2%$9.3M+22.6%$8.3M-13.6%$8.6M+40.6%$10.0M+44.9%$7.6M+79.4%
Operating Income-$42.9Mn/m-$39.6Mn/m-$41.4Mn/m-$39.3Mn/m-$38.7Mn/m-$44.4Mn/m-$47.4Mn/m-$41.0Mn/m
EBITDA-$42.6Mn/m-$39.1Mn/m-$41.0Mn/mN/A-$38.3Mn/m-$43.9Mn/m-$46.9Mn/mN/A
Interest Expense$728K+10300.0%$674K+4714.3%$667K+2568.0%N/A$7K-78.1%$14K-64.1%$25K-43.2%N/A
Net Income-$41.9Mn/m-$38.3Mn/m-$39.7Mn/m-$37.8Mn/m-$36.8Mn/m-$42.1Mn/m-$44.6Mn/m-$37.5Mn/m
EPS (Basic)-$0.68n/m-$0.63n/m-$0.66n/m-$0.79n/m-$0.85n/m-$0.97n/m-$1.03-$0.88
EPS (Diluted)-$0.68n/m-$0.63n/m-$0.66n/m-$0.79n/m-$0.85n/m-$0.97n/m-$1.03-$0.88
Diluted Shares (Avg)62M+42.7%61M+40.9%60M+39.8%N/A43M+0.6%43M+0.2%43MN/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.

KYTX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KYTX quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'25FilingQ4'2410-K
Total Assets$189.4M+1.2%$219.8M-3.0%$257.0M-1.4%$293.8M-3.6%$187.2M-44.8%$226.5M-37.6%$260.7M-33.2%$304.6M+305.1%
Current Assets$176.3M+0.8%$206.5M-3.6%$241.7M-2.4%$283.0M-2.6%$174.9M-46.2%$214.3M-38.6%$247.7M-34.0%$290.6M+379.0%
Cash & Equivalents$31.8M-6.9%$31.8M-40.5%$32.2M-43.4%$124.1M+28.4%$34.2M-67.4%$53.4M-59.4%$56.9M-74.6%$96.6M+178.9%
Short-Term Investments$138.8M+1.3%$167.6M+5.9%$204.3M+9.9%$155.2M-18.1%$137.0M-36.9%$158.2M-26.3%$185.8M+27.7%$189.4M+727.0%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$56.3M+59.8%$54.3M+28.8%$61.4M+67.7%$61.5M+61.7%$35.2M-3.5%$42.1M+42.3%$36.6M+26.4%$38.1M-56.9%
Current Liabilities$25.1M-25.8%$22.8M-42.7%$29.7M-10.9%$36.5M+8.1%$33.9M+9.3%$39.8M+69.5%$33.3M+52.3%$33.8M+70.0%
Non-Current Liabilities$31.1M+2226.1%$31.5M+1243.8%$31.8M+847.5%$25.1M+482.6%$1.3M-75.7%$2.3M-61.8%$3.4M-53.0%$4.3M-93.7%
Long-Term Debt$25.0M$24.9MN/A$24.7MN/AN/AN/AN/A
Total Equity$133.2M-12.4%$165.5M-10.2%$195.6M-12.7%$232.3M-12.9%$151.9M-49.8%$184.4M-44.7%$224.0M-37.9%$266.6Mn/m
Retained Earnings-$544.8Mn/m-$502.9Mn/m-$464.6Mn/m-$424.8Mn/m-$387.0Mn/m-$350.2Mn/m-$308.2Mn/m-$263.5Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.

KYTX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KYTX quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$35.4Mn/m-$40.3Mn/m-$41.6Mn/m-$33.5Mn/m-$43.3Mn/m-$31.9Mn/m-$44.9Mn/m-$37.1Mn/m
Depreciation & Amortization$274K-34.0%$434K-15.7%$351K-29.9%$368K-34.6%$415K-25.6%$515K-2.8%$501K+3.9%$563K+21.9%
Stock-Based Compensation$3.6M+34.1%$3.5M+39.3%$3.2M+46.7%N/A$2.7M-20.9%$2.5M+96.1%$2.2M-5.1%N/A
Capital Expenditures$174K+8600.0%N/AN/AN/A$2K-98.0%$4K-99.6%$0-100.0%$532K+59.3%
Free Cash Flow-$35.5Mn/mN/AN/AN/A-$43.3Mn/m-$32.0Mn/m-$44.9Mn/m-$37.6Mn/m
Investing Cash Flow$28.5M+26.4%$36.1M+23.9%-$50.2M-1000.0%-$17.3M-159.2%$22.6M+3236.8%$29.2Mn/m$5.6Mn/m$29.2M-7.8%
Financing Cash Flow$6.9M+360.8%$3.8Mn/m-$101Kn/m$140.7Mn/m$1.5Mn/m-$649Kn/m-$414K-100.1%-$215Kn/m

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

KYTX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KYTX quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Return on Equity-31.5%-7.3pp-23.2%-0.3pp-20.3%-0.4pp-16.3%-2.2pp-24.2%-12.8pp-22.8%-14.2pp-19.9%-12.5pp-14.1%
Return on Assets-22.1%-2.5pp-17.4%+1.1pp-15.5%+1.7pp-12.9%-0.6pp-19.7%-9.5pp-18.6%-10.7pp-17.1%-10.3pp-12.3%+15.2pp
Current Ratio7.01+1.8x9.06+3.7x8.15+0.7x7.75-0.9x5.16-5.3x5.39-9.5x7.44-9.7x8.61+5.6x
Debt-to-Equity0.190.15N/A0.11N/AN/AN/AN/A
Liabilities-to-Equity0.42+0.2x0.33+0.1x0.31+0.2x0.27+0.1x0.23+0.1x0.23+0.1x0.16+0.1x0.14

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Kyverna Therapeutics, Inc. KYTX FY2025 N/A -$161.3M N/A $276.3M —
Altimmune, Inc. ALT FY2025 $41K -$88.1M N/A $274.4M —
X4 Pharmaceuticals, Inc. XFOR FY2025 $35.1M -$79.2M N/A $302.3M 74/100
Lyell Immunopharma, Inc. LYEL FY2025 $36K -$274.4M N/A $333.9M —
Enanta Pharmaceuticals, Inc ENTA FY2026 $63.0M -$68.2M N/A $232.4M 63/100
Larimar Therapeutics, Inc. LRMR FY2025 N/A -$165.7M N/A $336.9M —

Frequently Asked Questions

No, Kyverna Therapeutics, Inc. (KYTX) reported a net loss of $161.3M in fiscal year 2025.

Kyverna Therapeutics, Inc. (KYTX) reported diluted earnings per share of -$3.64 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Kyverna Therapeutics, Inc. (KYTX) had EBITDA of -$168.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Kyverna Therapeutics, Inc. (KYTX) had $124.1M in cash and equivalents against $24.7M in long-term debt.

Kyverna Therapeutics, Inc. (KYTX) has a return on equity of -69.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Kyverna Therapeutics, Inc. (KYTX) recorded an outflow of $153.7M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Kyverna Therapeutics, Inc. (KYTX) recorded an outflow of $153.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Kyverna Therapeutics, Inc. (KYTX) had $293.8M in total assets as of fiscal year 2025, including both current and long-term assets.

Kyverna Therapeutics, Inc. (KYTX) invested $5K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Kyverna Therapeutics, Inc. (KYTX) invested $133.7M in research and development during fiscal year 2025.

Kyverna Therapeutics, Inc. (KYTX) had 60M shares outstanding as of fiscal year 2025.

Kyverna Therapeutics, Inc. (KYTX) had a current ratio of 7.75 as of fiscal year 2025, which is generally considered healthy.

Kyverna Therapeutics, Inc. (KYTX) had a debt-to-equity ratio of 0.11 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Kyverna Therapeutics, Inc. (KYTX) had a liabilities-to-equity ratio of 0.27 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Kyverna Therapeutics, Inc. (KYTX) had a return on assets of -54.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Kyverna Therapeutics, Inc. (KYTX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $276.3M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Kyverna Therapeutics, Inc. (KYTX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $276.3M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Kyverna Therapeutics, Inc. (KYTX) held $279.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $153.7M over that year. Dividing the one by the other, the reported balance equals about 22 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Kyverna Therapeutics, Inc. (KYTX) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Kyverna Therapeutics, Inc. (KYTX) reported a net loss of $161.3M while operations used $153.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Kyverna Therapeutics, Inc. (KYTX) reported an operating loss of $169.8M against $489K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Back to top